Therapeutic Class Overview Beta-Adrenergic Antagonists (Single-Entity)

Total Page:16

File Type:pdf, Size:1020Kb

Therapeutic Class Overview Beta-Adrenergic Antagonists (Single-Entity) Therapeutic Class Overview Beta-adrenergic antagonists (single-entity) · Therapeutic Class Overview/Summary: The beta-adrenergic blocking agents (β-blockers) are Food and Drug Administration (FDA)-approved for the treatment of angina, arrhythmias, essential tremor, heart failure, hypertension, hypertrophic aortic stenosis, migraine prophylaxis, myocardial infarction, and pheochromocytoma.1-26 The β-blockers differ with regards to their adrenergic-receptor blocking, membrane stabilizing and intrinsic sympathomimetic activities, as well as lipophilicity.1-26 There are at least three distinct types of β receptors distributed throughout the body (β1, β2, and β3). β1-receptors are located predominantly in the heart and kidneys. β2-receptors are located in the lungs, gastrointestinal tract, liver, uterus, vascular smooth muscle, and skeletal muscle. β3-receptors are located in fat cells. β-blockers primarily exert their effects through a blockade of β1 and β2 receptor subtypes. Agents that have a greater affinity for β1 receptors are considered to be cardioselective. These agents may be safer in patients with asthma, chronic obstructive pulmonary disease, and peripheral vascular disease because they produce less inhibition of β2 receptors, which mediate vasoconstriction and bronchospasm. Cardioselectivity is dose dependent; therefore, β2 blockade can occur at higher doses. Carvedilol and labetalol also block α-adrenergic receptors. 27-28 Current clinical guidelines identify β-blockers as effective in many indications. Their place in therapy varies depending on indication and other patient specific factors. Specific treatment guidelines are summarized in Table 12.29-61 The beta-adrenergic blocking agents that are included in this review are listed in Table 1 and comparative information on cardioselectivity is highlighted in Table 2. This review encompasses all dosage forms and strengths for the single-entity products. A significant majority of these agents are available as a generic product. Table 1. Current Medications Available in the Therapeutic Class1-26 Generic Food and Drug Administration-Approved Dosage Generic (Trade Name) Indications Form/Strength Availability Management of ventricular premature Capsule: Acebutolol HCl ® beats; hypertension alone or in combination 200 mg a (Sectral *) with other antihypertensives 400 mg To decrease angina frequency and increase Tablet: exercise tolerance due to coronary 25 mg atherosclerosis; hypertension alone or in 50 mg Atenolol ® combination with other antihypertensives; 100 mg a (Tenormin *) hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality Hypertension alone or in combination with Tablet: Betaxolol HCl ® other antihypertensives 10 mg a (Kerlone *) 20 mg Bisoprolol Hypertension alone or in combination with Tablet: fumarate other antihypertensives 5 mg a (Zebeta®*) 10 mg Essential hypertension, alone or in Tablet: combination with other antihypertensives; 3.125 mg mild to severe chronic heart failure of 6.25 mg Carvedilol ischemic or cardiomyopathic origin to 12.5 mg ® a (Coreg *) increase survival and, also, to reduce the 25 mg risk of hospitalizations; reduce cardiovascular mortality in clinically stable patients who have survived the acute phase Page 1 of 10 Copyright 2015 • Review Completed on 8/3/2015 Therapeutic Class Overview: beta adrenergic antagonists (single entity) Generic Food and Drug Administration-Approved Dosage Generic (Trade Name) Indications Form/Strength Availability of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) Essential hypertension, alone or in Extended-release combination with other antihypertensives; capsule: mild to severe chronic heart failure of 10 mg ischemic or cardiomyopathic origin to 20 mg Carvedilol increase survival and, also, to reduce the 40 mg Phosphate (Coreg risk of hospitalizations; reduce 80 mg - CR) cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) Intraoperative and Postoperative Injection: Tachycardia and/or Hypertension that occur 10 mg/mL during induction and tracheal intubation, during surgery, on emergence from IV solution anesthesia and in the postoperative period; (Brevibloc®): Esmolol ® Supraventricular Tachycardia or 10 mg/mL a (Brevibloc *) Noncompensatory Sinus Tachycardia, short 20 mg/mL term control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances Hypertension alone or in combination with Injection: other antihypertensives (tablet); 5 mg/mL Hypertension, control of blood pressure in Labetalol HCl ® severe hypertension (injection) Tablet: a (Trandate *) 100 mg 200 mg 300 mg Angina, long-term maintenance treatment; Injection: Hypertension alone or in combination with 5 mg/5 mL other antihypertensives; Hemodynamically Metoprolol tartrate stable patients with definite or suspected Tablet: ® a (Lopressor *) acute myocardial infarction to reduce 25 mg cardiovascular mortality 50 mg 100 mg Angina, long-term maintenance treatment; Extended-release Hypertension alone or in combination with tablet: other antihypertensives; Stable, 25 mg Metoprolol symptomatic (NYHA Class II or III) heart 50 mg succinate (Toprol failure of ischemic, hypertensive, or a ® 100 mg XL *) cardiomyopathic origin; Hemodynamically 200 mg stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality Nadolol Angina, long-term maintenance treatment; Tablet: ® a (Corgard *) Hypertension alone or in combination with 20 mg Page 2 of 10 Copyright 2015 • Review Completed on 8/3/2015 Therapeutic Class Overview: beta adrenergic antagonists (single entity) Generic Food and Drug Administration-Approved Dosage Generic (Trade Name) Indications Form/Strength Availability other antihypertensives 40 mg 80 mg Hypertension alone or in combination with Tablet: other antihypertensives 2.5 mg Nebivolol HCl ® 5 mg - (Bystolic *) 10 mg 20 mg Mild to moderate arterial hypertension alone Tablet: Penbutolol sulfate ® or in combination with other 20 mg - (Levatol ) antihypertensives Hypertension alone or in combination with Tablet: Pindolol other antihypertensives 5 mg a 10 mg To decrease angina frequency and increase capsule: exercise tolerance due to coronary 60 mg atherosclerosis (24-hour capsule); 80 mg Persistent premature ventricular 120 mg extrasystoles that impair the well-being of 160 mg the patient and do not respond to conventional measures (injection); Short- Injection: term treatment of supraventricular 1 mg/mL tachycardia, including Wolff-Parkinson- White syndrome and thyrotoxicosis, to Oral solution: decrease ventricular rate (injection); To 20 mg/5 mL abolish tachyarrhythmias due to excessive 40 mg/5 mL catecholamine action during anesthesia when other measures fail (injection); To control ventricular rate in life-threatening Oral Solution Propranolol HCl digitalis-induced arrhythmias (injection); To (Hemangeol®): (Hemangeol®, control ventricular rate in patients with atrial 4.28 mg/mL ® Inderal LA *, fibrillation and a rapid ventricular a Inderal XL®, response(tablet); Hypertension alone or in Tablet: Innopran XL®) combination with other antihypertensives; 10 mg Improves NYHA functional class in 20 mg symptomatic patients with hypertropic 40 mg subaortic stenosis (24-hour capsule); 60 mg Reduce cardiovascular mortality in patients 80 mg who have survived the acute phase of myocardial infarction and are clinically stable (tablet); Adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine- secreting tumors (tablet); Familial or hereditary essential tremor (injection); Treatment of proliferating infantile hemangioma requiring systemic therapy (oral solution); Prophylaxis of migraine headache (24-hour capsule) Sotalol HCl Documented ventricular arrhythmias that in Injection: (Betapace®*, the judgement of the physician are life- 150 mg/10 mL ® a Betapace AF *, threatening; Maintenance of normal sinus Sotylize®, rhythm in patients with symptomatic atrial Oral Solution Page 3 of 10 Copyright 2015 • Review Completed on 8/3/2015 Therapeutic Class Overview: beta adrenergic antagonists (single entity) Generic Food and Drug Administration-Approved Dosage Generic (Trade Name) Indications Form/Strength Availability Sorine®†) fibrillation/atrial flutter who are currently in (Sotylize®): sinus rhythm 5 mg/mL Tablet: 80 mg 120 mg 160 mg 240 mg Hypertension alone or in combination with Tablet: other antihypertensives; Reduce 5 mg cardiovascular mortality and reinfarction in 10 mg Timolol Maleate a patients who have survived the acute phase 20 mg of myocardial infarction and are clinically stable; Prophylaxis of migraine headache HCl=hydrochloride * Generic available in at least one formulation † Branded generic product Evidence-based Medicine · Despite the extensive experience with β-blockers in clinical practice, there have been no studies suggesting that any of these agents have major advantages or disadvantages in relation to the others for the treatment of many cardiovascular diseases. When any available β-blocker is titrated properly, it can be effective in patients with an arrhythmia, hypertension, or angina pectoris and other indications.63-185 · The safety and efficacy of sotalol hydrochloride oral
Recommended publications
  • Drug Class Review Beta Adrenergic Blockers
    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
    [Show full text]
  • Adrenergic Antagonist
    PHARMACOLOGY Adrenergic antagonist OBJECTIVES: • Describe the different classifications for drugs that can block sympathetic nervous system. •Describe the kinetics, dynamics, uses and side effects of alpha adrenergic drugs. • Identify Difference between selective and non selective alpha blockers. • Know the difference between tamsulosin and other selective alpha receptor blockers. •Identify the different classifications for beta receptors blockers. •Describe the kinetics, dynamics, uses and side effects of beta adrenergic drugs. •Know the preferable drug for diseases as hypertension, glaucoma, arrythmia, myocardial infarction, anxiety, migraine and ect…. • Important. • Extra notes It’s a recall, if you know it you can skip it! Adrenergic receptors Adrenergic receptors Dopaminergic adrenoceptors adrenoceptors α− β− receptors β3 α1 α2 β1 β2 e.g. D1 α1 β2 β1 β3 Post-synaptic excitatory in function (cause inhibitory in function excitatory in In adipose contraction) except in GIT. (cause relaxation) function, present tissue mainly in heart Present mainly in smooth muscles. Contraction of pregnant Relaxation of the uterus ↑ heart rate: ↑ lipolysis uterus. (Delay premature labor) + chronotropic ↑ free fatty effect, Vasoconstriction of skin & Relaxation of skeletal & acids. Tachycardia peripheral blood vessels coronary blood vessels →increased peripheral (vasodilatation) ↑ force of → resistance hypertension. contraction : Relaxation of GIT muscles & urinary bladder’s muscles. + inotropic effect Contraction of GIT sphincter (constipation) & urinary
    [Show full text]
  • Advantages and Disadvantages of Beta- Adrenergic Blocking Drugs in Hypertension
    Reprinted from ANCIOLOCY Vol. 29, No. -I April 1978 Copyright 0 1978 Prinred in U.S.A. All Rights Rewrced Advantages and Disadvantages of Beta- Adrenergic Blocking Drugs in Hypertension Eoin T. O'Brien DUBLIN, IRELAND General Measures Elevation of blood pressure should be regarded as one of a number of potential risk factors for cardiovascular disease-albeit a major risk factor- rather than a disease per se.' It is important to identify additional risk factors in the hypertensive patient, not only because collectively these factors may greatly magnify the cardiovascular risk, but also because modification of them may, of itself, lower the blood pressure and thus alleviate the risk and save the patient the inconvenience, expense, and potential harm that may result from even the simplest of drug regimes. Careful consideration should be given to the patient's diet (particularly in relation to the calorie intake in the case of obesity, the cholesterol and saturated fat content in the case of hyperlipidemia and patients at high risk, and the salt content) and to smoking habits, physical activity. stress. personality, and drug therapy, especially anovulant preparations. Other diseases, such as diabetes mellitus, which are associated with a high incidence of hypertension and pri- mary causes of hypertension must be excluded. Although there is still no statistical evidence to show that modification of these risk factors-with the exception of tobacco and anovulant preparations-will actually reduce mortal- ity, it does seem prudent on the basis of the evidence available to encourage the hypertensive patient to adjust his or her life-style not only to reduce the cardiovascular risk,2 but also because in many instances the mildly hypertensive patient will respond to this approach alone.
    [Show full text]
  • Drug Class Review Antianginal Agents
    Drug Class Review Antianginal Agents 24:12.08 Nitrates and Nitrites 24:04.92 Cardiac Drugs, Miscellaneous Amyl Nitrite Isosorbide Dinitrate (IsoDitrate ER®, others) Isosorbide Mononitrate (Imdur®) Nitroglycerin (Minitran®, Nitrostat®, others) Ranolazine (Ranexa®) Final Report May 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Antianginal Therapies .............................................................................................. 4 Table 2. Summary of Agents .................................................................................................. 5 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Clinical Practice Guidelines .................................................... 9 Pharmacology ............................................................................................................................... 10 Table 4. Pharmacokinetic Properties
    [Show full text]
  • Guanfacine Extended Release for ADHD
    Out of the Pipeline p Guanfacine extended release for ADHD Floyd R. Sallee, MD, PhD uanfacine extended release (GXR)— Table 1 α Once-daily a selective -2 adrenergic agonist Guanfacine extended release: GFDA-approved for the treatment formulation may of attention-defi cit/hyperactivity disor- Fast facts improve adherence der (ADHD)—has demonstrated effi cacy Brand name: Intuniv and control for inattentive and hyperactive/impulsive Indication: Attention-defi cit/hyperactivity symptoms across disorder symptom domains in 2 large trials lasting® Dowden Health Media a full day 8 and 9 weeks.1,2 GXR’s once-daily formu- Approval date: September 3, 2009 lation may increase adherence and deliver Availability date: November 2009 consistent control of symptomsCopyright across a For personalManufacturer: use Shire only full day (Table 1). Dosing forms: 1-mg, 2-mg, 3-mg, and 4-mg extended-release tablets Recommended dosage: 0.05 to 0.12 mg/kg Clinical implications once daily GXR exhibits enhancement of noradren- ergic pathways through selective direct receptor action in the prefrontal cortex.3 brain believed to play a major role in at- This mechanism of action is different from tentional and organizational functions that that of other FDA-approved ADHD medi- preclinical research has linked to ADHD.3 cations. GXR can be used alone or in com- The postsynaptic α-2A receptor is bination with stimulants or atomoxetine thought to play a central role in the opti- for treating complex ADHD, such as cases mal functioning of the PFC as illustrated accompanied by oppositional features and by the “inverted U hypothesis of PFC ac- emotional dysregulation or characterized tivation.”4 In this model, cyclic adenos- by partial stimulant response.
    [Show full text]
  • The Adrenergic Control of Lower Esophageal Sphincter Function: an EXPERIMENTAL MODEL of DENERVATION SUPERSENSITIVITY
    The Adrenergic Control of Lower Esophageal Sphincter Function: AN EXPERIMENTAL MODEL OF DENERVATION SUPERSENSITIVITY Anthony J. DiMarino, Sidney Cohen J Clin Invest. 1973;52(9):2264-2271. https://doi.org/10.1172/JCI107413. To evaluate the adrenergic regulation of lower esophageal sphincter (LES) function, LES pressure, LES relaxation during swallowing, and blood pressure were measured in the anesthetized opossum, Didelphis virginiana, during intravenous administration of alpha and beta adrenergic agonists and antagonists. Studies were done in controls and animals adrenergically denervated with 6-hydroxydopamine. Alpha adrenergic agonists (norepinephrine, phenylephrine) increased LES pressure and blood pressure, whereas a beta adrenergic agonist (isoproterenol) decreased both pressures. Alpha adrenergic antagonism (phentolamine) reduced basal LES pressure by 38.3±3.8% (mean ±SEM) (P < 0.001). Beta adrenergic antagonism (propranolol) had no significant effect on either basal LES pressure or percent of LES relaxation with swallowing. After adrenergic denervation with 6-hydroxydopamine, basal LES pressure was reduced by 22.5±5.3% (P < 0.025) but LES relaxation during swallowing was unaltered. In denervated animals, both LES pressure and blood pressure dose response curves showed characteristics of denervation supersensitivity to alpha but not to beta adrenergic agonists. These studies suggest: (a) a significant portion of basal LES pressure is dependent upon alpha adrenergic stimulation; (b) LES relaxation during swallowing is not an adrenergically mediated response; c( ) the LES pressure response to alpha adrenergic agonists after 6-hydroxydopamine may serve as a model of denervation supersensitivity in the gastrointestinal tract. Find the latest version: https://jci.me/107413/pdf The Adrenergic Control of Lower Esophageal Sphincter Function AN EXPERIMENTAL MODEL OF DENERVATION SUPERSENSITIVITY ANTHoNY J.
    [Show full text]
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information
    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
    [Show full text]
  • IHS National Pharmacy & Therapeutics Committee National
    IHS National Pharmacy & Therapeutics Committee National Core Formulary; Last Updated: 09/23/2021 **Note: Medications in GREY indicate removed items.** Generic Medication Name Pharmacological Category (up-to-date) Formulary Brief (if Notes / Similar NCF Active? available) Miscellaneous Medications Acetaminophen Analgesic, Miscellaneous Yes Albuterol nebulized solution Beta2 Agonist Yes Albuterol, metered dose inhaler Beta2 Agonist NPTC Meeting Update *Any product* Yes (MDI) (Nov 2017) Alendronate Bisphosphonate Derivative Osteoporosis (2016) Yes Allopurinol Antigout Agent; Xanthine Oxidase Inhibitor Gout (2016) Yes Alogliptin Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor DPP-IV Inhibitors (2019) Yes Anastrozole Antineoplastic Agent, Aromatase Inhibitor Yes Aspirin Antiplatelet Agent; Nonsteroidal Anti-Inflammatory Drug; Salicylate Yes Azithromycin Antibiotic, Macrolide STIs - PART 1 (2021) Yes Calcium Electrolyte supplement *Any formulation* Yes Carbidopa-Levodopa (immediate Anti-Parkinson Agent; Decarboxylase Inhibitor-Dopamine Precursor Parkinson's Disease Yes release) (2019) Clindamycin, topical ===REMOVED from NCF=== (See Benzoyl Peroxide AND Removed January No Clindamycin, topical combination) 2020 Corticosteroid, intranasal Intranasal Corticosteroid *Any product* Yes Cyanocobalamin (Vitamin B12), Vitamin, Water Soluble Hematologic Supplements Yes oral (2016) Printed on 09/25/2021 Page 1 of 18 National Core Formulary; Last Updated: 09/23/2021 Generic Medication Name Pharmacological Category (up-to-date) Formulary Brief
    [Show full text]
  • The Importance of Serotonergic and Adrenergic Receptors for the Induction and Expression of One-Trial Cocaine-Induced Behavioral Sensitization" (2016)
    California State University, San Bernardino CSUSB ScholarWorks Electronic Theses, Projects, and Dissertations Office of aduateGr Studies 12-2016 THE IMPORTANCE OF SEROTONERGIC AND ADRENERGIC RECEPTORS FOR THE INDUCTION AND EXPRESSION OF ONE- TRIAL COCAINE-INDUCED BEHAVIORAL SENSITIZATION Krista N. Rudberg California State University - San Bernardino Follow this and additional works at: https://scholarworks.lib.csusb.edu/etd Part of the Biological Psychology Commons, and the Pharmacology Commons Recommended Citation Rudberg, Krista N., "THE IMPORTANCE OF SEROTONERGIC AND ADRENERGIC RECEPTORS FOR THE INDUCTION AND EXPRESSION OF ONE-TRIAL COCAINE-INDUCED BEHAVIORAL SENSITIZATION" (2016). Electronic Theses, Projects, and Dissertations. 420. https://scholarworks.lib.csusb.edu/etd/420 This Thesis is brought to you for free and open access by the Office of aduateGr Studies at CSUSB ScholarWorks. It has been accepted for inclusion in Electronic Theses, Projects, and Dissertations by an authorized administrator of CSUSB ScholarWorks. For more information, please contact [email protected]. THE IMPORTANCE OF SEROTONERGIC AND ADRENERGIC RECEPTORS FOR THE INDUCTION AND EXPRESSION OF ONE-TRIAL COCAINE- INDUCED BEHAVIORAL SENSITIZATION A Thesis Presented to the Faculty of California State University, San Bernardino In Partial Fulfillment of the Requirements for the Degree Master of Arts in General/Experimental Psychology by Krista Nicole Rudberg December 2016 THE IMPORTANCE OF SEROTONERGIC AND ADRENERGIC RECEPTORS FOR THE INDUCTION AND EXPRESSION OF ONE-TRIAL COCAINE- INDUCED BEHAVIORAL SENSITIZATION A Thesis Presented to the Faculty of California State University, San Bernardino by Krista Nicole Rudberg December 2016 Approved by: Sanders McDougall, Committee Chair, Psychology Cynthia Crawford, Committee Member Matthew Riggs, Committee Member © 2016 Krista Nicole Rudberg ABSTRACT Addiction is a complex process in which behavioral sensitization may be an important component.
    [Show full text]
  • Different Effects of Propranolol, Bisoprolol, Carvedilol and Doxazosin on Heart Rate, Blood Pressure, and Plasma Concentrations of Epinephrine and Norepinephrine K
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 2003; 6 (1-4), 69-72 Different Effects of Propranolol Bisoprolol, Carvedilol and Doxazosin on Heart Rate, Blood Pressure, and Plasma Concentrations of Epinephrine and Norepinephrine Stoschitzky K, Donnerer J, Klein W, Koshucharova G Kraxner W, Lercher P, Maier R, Watzinger N, Zweiker R Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria ORIGINAL PAPERS, CLINICAL CARDIOLOGY Alpha- Versus Beta-Blockers J Clin Basic Cardiol 2003; 6: 69 Different Effects of Propranolol, Bisoprolol, Carvedilol and Doxazosin on Heart Rate, Blood Pressure, and Plasma Concentrations of Epinephrine and Norepinephrine K. Stoschitzky1, G. Koshucharova1, R. Zweiker1, P. Lercher1, R. Maier1, N. Watzinger1, W. Kraxner1, W. Klein1, J. Donnerer2 Background: Despite of its beta-blocking effects, carvedilol has been shown not to decrease resting heart rate in healthy subjects. Therefore, we compared haemodynamic effects of carvedilol (an alpha- and beta-blocker), propranolol (a non-selec- tive beta-blocker), bisoprolol (a beta1-selective beta-blocker), doxazosin (an alpha-blocker) and placebo, at rest and during exercise. In addition, we measured plasma levels of epinephrine and norepinephrine. Methods: Twelve healthy males received single oral doses of 80 mg propranolol, 5 mg bisoprolol, 50 mg carvedilol, 4 mg doxazosin and placebo according to a randomized, double-blind, crossover protocol. Three hours after drug intake, heart rate and blood pressure were measured at rest, after 10 min of exercise, and after 15 min of recovery.
    [Show full text]
  • F3-Adrenergic Antagonist (Receptors/Cyclic AMP/Aminobenzylpropranolol/Iodohydroxybenzylpindolol/Isoproterenol) WESLEY L
    Proc. Natl. Acad. Sci. USA Vol. 76, No. 12, pp. 6401-6405, December 1979 Cell Biology Quantitative relationship between 3-adrenergic receptor number and physiologic responses as studied with a long-lasting f3-adrenergic antagonist (receptors/cyclic AMP/aminobenzylpropranolol/iodohydroxybenzylpindolol/isoproterenol) WESLEY L. TERASAKI, JOEL LINDEN, AND GARY BROOKER* Department of Pharmacology, School of Medicine, University of Virginia, Charlottesville, Virginia 22908 Communicated by Paul Greengard, August 20, 1979 ABSTRACT The aminobenzyl analog of propranolol, atrium when f3-adrenergic receptor number is selectively de- 1- (p-amino-a,a-dimethylphenethylamino)-3(1-naphthoxy)2- creased. To investigate this problem, a new propanol, was synthesized and found tobe a potent B-adrenergic f3-adrenergic blocking agent. The fl-adrenergic receptors of cultured rat C6 blocking agent, 1-(p-amino-a,a-dimethylphenethylamino- glioma cells (2B clone) as assessed by [' 51]iodohydroxybenzyl- 3-(1-naphthoxy)-2-propanol (aminobenzylpropranolol), was pindolol binding were decreased 50 and >95% afterpretreat- synthesized. It was found to be a selective agent for the elimi- ment with 8 nM and 1 ,M aminobenzylpropranolol, respec- nation of cellular /3-adrenergic receptors. tively. Unlike propranolol, aminobenzylpropranolol displayed a prolonged blockade of receptors that was maintained during several hours of washing. [121s]Iodohydroxybenzylpindolol MATERIALS AND METHODS saturation binding experiments in cells exposed to aminoben- Tissue Culture. C6 rat glioma cells, 2B subclone (7), were zylpropranolol and subsequently washed indicated that the compound effectively diminished receptor number with no grown in monolayer cultures as described (1) in 16-mm plastic change in the affinity of the remaining receptors for iodohy- cluster dishes. In all experiments, the cells were changed from droxybenzylpindolol.
    [Show full text]
  • Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
    PREVENTION, DETECTION, EVALUATION, AND MANAGEMENT OF HIGH BLOOD PRESSURE IN ADULTS Thomas F. Whayne, Jr, MD, PhD, FACC, FAHA, FACP Professor of Medicine (Cardiology) University of Kentucky Gill Heart Institute NOVEMBER 2018 No conflicts to disclose Email: [email protected] (0 number zero) (0 is the number zero) Educational Need/Practice Gap Regarding hypertension, the major practice gap is failure to adequately control BP. Tight BP control as in JNC-7 is less with unofficial JNC-8 (2013) but nevertheless, the need for adequate treatment must still be emphasized. Now, the 2015 NIH study appears more like JNC-7, followed by additional guidelines, all adding to the confusion. Good judgment in clinical practice is still the order of the day. Objectives • Review the latest guidelines and evidence- based medicine for the treatment of hypertension. • Discuss specific mechanisms involved in the causation of hypertension and how this affects treatment. • Summarize specific invasive techniques for the difficult patient whose hypertension does not respond to medications. Expected Outcome Approximately 75% of hypertensive patients are not adequately managed. This is in part the fault of many patients but also there is failure of clinicians to push for maximal beneficial results. Hopefully, a consideration of available information and medications will emphasize the possibilities for improved BP control. Hypertension pts. (50 million: 24% of US population): Treatment and Control % of Hypertensives % on Rx Achieving taking Medications BP Control 24% Controlled on Rx Not 53% Not on Rx on Rx on Rx 29% Not Controlled on Rx NHANES III, The Centers for Disease Control and Prevention, and the National Center for Health Statistics, Burt et.
    [Show full text]